![Iris Tavor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Iris Tavor
General Counsel at ENLIVEX THERAPEUTICS LTD.
Profile
Iris Tavor is currently a Senior Director of Regulatory and Quality Affairs at Enlivex Therapeutics Ltd.
She previously worked as the Head of Quality and Regulatory Affairs at Pluristem Ltd.
Iris Tavor active positions
Companies | Position | Start |
---|---|---|
ENLIVEX THERAPEUTICS LTD. | General Counsel | - |
Former positions of Iris Tavor
Companies | Position | End |
---|---|---|
Pluristem Ltd.
![]() Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | General Counsel | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private companies | 1 |
---|---|
Pluristem Ltd.
![]() Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
- Stock Market
- Insiders
- Iris Tavor